Clinical Trials in Canada

Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization Group 1 PAH.

The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the pharmacokinetics of understudied drugs currently being administered to children per standard of care as prescribed by their treating provider.

The primary objective of this open-label, long-term follow-up study is to evaluate the long-term safety and tolerability of sotatercept when added to background pulmonary arterial hypertension (PAH) therapy in adult participants with PAH who have completed prior sotatercept studies. The secondary objective is to evaluate continued efficacy in adult participants with PAH who have completed prior sotatercept studies.

This study aims to demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after radiotherapy.

The goal of this observational study is to learn about heart function and high lung blood pressure in patients with heart failure. The main question it aims to answer is whether we can improve the ability to predict patients who will have complications after they receive treatment including heart transplant and left ventricular assist devices.

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with combined postcapillary and precapillary pulmonary hypertension (Cpc-PH) due to heart failure with preserved ejection fraction (HFpEF). Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).

The investigators' central hypothesis is that early combination therapy with two pulmonary-arterial-hypertension-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.

Many patients with chronic thromboembolic pulmonary hypertension (CTEPH) are treated with balloon pulmonary angioplasty [BPA] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area [FCSA] is recovered during BPA. We plan to measure FCSAIn CTEPH patients, before and after a session of BPA.

The goal of this observational patient registry is to learn how expert centers treat patients with chronic thromboembolic pulmonary hypertension (CTEPH).

The PROSERA Study is a Phase 3 clinical research study designed to help researchers understand whether an inhaled investigational product called seralutinib may be an effective and safe future treatment for adults with pulmonary arterial hypertension. The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

This study will evaluate the efficacy of oral levosimendan compared with placebo in subjects with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.

A phase 1B open-label, multiple ascending dose study assessing the pharmacokinetics, safety, pharmacodynamics, and efficacy of HS135 added to background pulmonary arterial hypertension therapy.

The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.